Amyloidosis is a disorder in which abnormal, misfolded proteins build up in tissues and organs, preventing them from working properly. Clumps of the abnormal proteins are called amyloid deposits. In patients with light chain amyloidosis, abnormal plasma cells produce a type of protein called an “immunoglobulin light-chain protein.” Amyloidosis may be treated with chemotherapy, but the disease often returns.
The purpose of this study is to find the highest dose of an investigational drug called NEOD001 that can be given safely in patients with light chain amyloidosis, and to observe its preliminary effectiveness as a treatment for the organ problems that are the result of light chain amyloidosis. NEOD001 is an antibody that targets a protein believed to be involved in light chain amyloidosis. It is given intravenously (by vein).